Boehringer Ingelheim Launches External Innovation Hub in China
Boehringer Ingelheim Launches External Innovation Hub in China
Search
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Our People, Our Culture
Our People, Our Culture
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
The Burdens of Schizophrenia
It can be hard for people living without schizophrenia to realize its burdens. Understanding these challenges can provide insights to help patients in need.
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Expert insights: top online lung cancer questions answered
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Skin and Inflammatory Diseases
skin diseases
Fremont, CA site
Fremont, CA site
Brigitte Fuhr
Our data transformation
Sites Around the World
Click here to view our biggest sites. With 52,000 employees worldwide, Boehringer Ingelheim has a research and production network across the globe.
Nick Gollop
Nick Gollop loves making a difference for patients and their families as a Senior Global Clinical Programme Leader in Clinical Development.
Scleroderma
Scleroderma
Contact Us
Contact Us
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Lung Diseases
Our Therapeutic Areas
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
Sustainable Development for Generations | Boehringer Ingelheim US
At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.
Vision & Values
Vision & Values
Social Impact | COVID-19 | Boehringer Ingelheim US
Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
Talking drug discovery with our U.S. research site head, Carine Boustany
Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.